enGene Holdings (ENGN) EBITDA Margin: History & Chart

enGene Holdings Inc.(ENGN)

Biotechnology · Montreal, QC

$1.83-0.04 (-2.14%)

Delayed quote: Oct 6, 2026, 11:24 AM EDT

About enGene Holdings Inc.

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Montreal, QC

82 employees

www.engene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ronald H. W. Cooper

View full financials

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
enGene Holdings Inc. (ENGN)	$122.59M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$122.13M	-1691.15%	-1668.02%	-8474.77%	-5696.48%
TuHURA Biosciences, Inc. (HURA)vs ›	$121.00M	N/A	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. (NRXP)vs ›	$125.34M	-1312.73%	-1312.73%	-1312.73%	-1312.73%
LENZ Therapeutics, Inc. (LENZ)vs ›	$118.80M	-475.96%	-475.96%	-272.89%	-272.89%
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$118.02M	-699.90%	-1930.94%	-1689.05%	-1903.35%
Caribou Biosciences, Inc. (CRBU)vs ›	$117.53M	-1187.82%	-1407.84%	-970.99%	-809.42%
Entera Bio Ltd. (ENTX)vs ›	$127.91M	-27378.57%	-16324.37%	-14117.74%	-9505.20%
Genelux Corporation (GNLX)vs ›	$116.36M	-408000.00%	-396456.25%	-201636.71%	-201636.71%
Coya Therapeutics, Inc. (COYA)vs ›	$116.00M	-254.71%	-369.64%	-290.17%	-290.17%

NAME

MARKET CAP

EBITDA MARGIN

TTM

enGene Holdings Inc. (ENGN)

$122.59M

N/A

Cibus, Inc. (CBUS)vs ›

$122.13M

-1691.15%

-1668.02%

-8474.77%